insights_auto
Why is NVAX up 15.80%?
Dive Deeperchevron_right
NVAX:NASDAQ
Novavax Inc
$12.75
arrow_upward
+15.80%(+1.74) 1D
$12.69
arrow_downward
-0.49% (-0.063)bedtimeAfter hours
Closed: Oct 9, 4:00:00 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for NVAX...
Open
$11.17
High
$13.04
Low
$11.03
Mkt. cap
2.10B
Avg. vol.
6.76M
Volume
19.03M
52-wk high
$13.38
52-wk low
$6.20
EPS
-$1.52
Beta
2.44
Shares outstanding
164.95M
No. of employees
749
Open
$11.17
High
$13.04
Low
$11.03
Mkt. cap
2.10B
Avg. vol.
6.76M
Volume
19.03M
52-wk high
$13.38
52-wk low
$6.20
EPS
-$1.52
Beta
2.44
Shares outstanding
164.95M
No. of employees
749
News stories
From web sources and news partners
Simply Wall Street
·
1 day ago
Novavax (NVAX) Could Be 82% Overvalued On Plague Headlines And Pfizer Deal Focus
24/7 Wall St.
·
2 days ago
Novavax Soars 16%, Moderna Surges 11%, Merck Climbs 3% as Biotech Rallies
Timothy Sykes
·
2 days ago
NVAX Stock Grinds Higher As Traders Watch Volatile Rebound
TradingView
·
2 days ago
Novavax, Inc. Stock 12‑Month Price Target Raised to $14.86, Implies 35% Upside
Profile
Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company developed the Novavax COVID-19 vaccine, now commercialized by Sanofi. The company also develops vaccines for influenza, respiratory syncytial virus, avian flu, shingles, Clostridioides difficile, and malaria.
Novavax develops proprietary immune-stimulating saponin-based immunologic adjuvants at a wholly owned Swedish subsidiary, Novavax AB. One of these, Matrix-M, is used in the Novavax COVID-19 vaccine. Wikipedia
About Novavax Inc
CEOJohn C. Jacobs
Employees749
Founded1987
HeadquartersGaithersburg, Maryland, United States
SectorBiotechnology
Websitenovavax.com